Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats

References

• Aillon K L, Xie Y, El-Gendy N, et al. (2009). Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev 61:457–66
   PubMed Web of Science ®Google Scholar
• Bailey MM, Berkland CJ. (2009). Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29:196–212
   PubMed Web of Science ®Google Scholar
• Carlisle R, Galambos JT. (1979). The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 24:358–62
   Google Scholar
• Chan JGY, Chan H-K, Prestidge CA, et al. (2013). A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm 83:285–92
   PubMed Web of Science ®Google Scholar
• Chow AL, Tong HY, Chattopadhyay P, Shekunov B. (2007). Particle engineering for pulmonary drug delivery. Pharm Res 24:411–37
   PubMed Web of Science ®Google Scholar
• Coowanitwong I, Arya V, Kulvanich P, Hochhaus GN. (2008). Slow release formulations of inhaled rifampin. AAPS J 10:342–8
   PubMed Web of Science ®Google Scholar
• Du Toit LC, Pillay V, Danckwerts MP. (2006). Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 7:118--35
   PubMed Web of Science ®Google Scholar
• Dube D, Agrawal GP, Vyas SP. (2012). Tuberculosis: from molecular pathogenesis to effective drug carrier design. Drug Discov Today 17:760–73
   PubMed Web of Science ®Google Scholar
• Duncan K, Barry III CE. (2004). Prospects for new antitubercular drugs. Curr Opin Microbiol 7:460–5
   PubMed Web of Science ®Google Scholar
• Gohel MC, Sarvaiya KG. (2007). A novel solid dosage form of rifampicin and isoniazid with improved functionality. AAPS PharmSciTech 8:E133–9
   Google Scholar
• Hirota K, Tomoda K, Inagawa H, et al. (2008). Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm Res 25:1420–30
   PubMed Web of Science ®Google Scholar
• Kaur J, Muttil P, Verma RK, et al. (2008). A hand-held apparatus for nose-only exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci 34:56–65
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Oosting M, Joosten LA, et al. (2011). Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 11:1--12
   Google Scholar
• Kolodziej H, Kiderlen AF. (2007). In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 14:18--26
   PubMedGoogle Scholar
• Lal S, Singhal S, Burley D, Crossley G. (1972). Effect of rifampicin and isoniazid on liver function. BMJ 1:148--50
   PubMed Web of Science ®Google Scholar
• Maartens G, Wilkinson RJ. (2007). Tuberculosis. Lancet 370:2030–43
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz J. (1997). Nitric oxide and antimicrobial activity of reactive oxygen intermediates. Immunopharmacology 37:35–41
   Google Scholar
• Marques MR, Loebenberg R, Almukainzi M. (2011). Simulated biological fluids with possible application in dissolution testing. Dissolution Technol 18:15–28
   Web of Science ®Google Scholar
• Misra A, Hickey AJ, Rossi C, et al. (2011). Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91:71–81
   PubMed Web of Science ®Google Scholar
• Murphy MP. (1999). Nitric oxide and cell death. Biochim Biophys Acta 1411:401–14
   PubMed Web of Science ®Google Scholar
• Muttil P, Kaur J, Kumar K, et al. (2007). Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci 32:140–50
   PubMed Web of Science ®Google Scholar
• Nathan CF, Hibbs Jr JB. (1991). Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 3:65–70
   PubMed Web of Science ®Google Scholar
• O'hara P, Hickey AJ. (2000). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 17:955–61
   PubMed Web of Science ®Google Scholar
• Ober CA, Kalombo L, Swai H, Gupta RB. (2012). Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol 236:132–8
   Web of Science ®Google Scholar
• Ohashi K, Kabasawa T, Ozeki T, Okada H. (2009). One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 135:19–24
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85:227–34
   PubMed Web of Science ®Google Scholar
• Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. (2004). Nitric oxide in health and disease of the respiratory system. Physiol Rev 84:731–65
   PubMed Web of Science ®Google Scholar
• Roa WH, Azarmi S, Al-Hallak MHDK, et al. (2011). Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 150:49–55
   PubMed Web of Science ®Google Scholar
• Rojanarat W, Changsan N, Tawithong E, et al. (2011). Isoniazid proliposome powders for inhalation preparation, characterization and cell culture studies. Int J Mol Sci 12:4414–34
   PubMed Web of Science ®Google Scholar
• Sen H, Jayanthi S, Sinha R, et al. (2003). Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof. U.S. Patent Application 10/685,567
   Google Scholar
• Sharma R, Muttil P, Yadav AB, et al. (2007). Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 59:499–506
   PubMed Web of Science ®Google Scholar
• Shishoo CJ, Shah SA, Rathod IS, et al. (1999). Stability of rifampicin in dissolution medium in presence of isoniazid. Int J Pharm 190:109–23
   PubMed Web of Science ®Google Scholar
• Son Y-J, Mcconville JT. (2011). A new respirable form of rifampicin. Eur J Pharma Biopharm 78:366–76
   PubMed Web of Science ®Google Scholar
• Sosnik A, Carcaboso ÃNM, Glisoni RJ, et al. (2010). New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 62:547–59
   PubMed Web of Science ®Google Scholar
• Suarez S, O'hara P, Kazantseva M, et al. (2001). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 18:1315–19
   PubMed Web of Science ®Google Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. (2009). Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 26:1847–55
   PubMed Web of Science ®Google Scholar
• Verma RK, Kaur J, Kumar K, et al. (2008). Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother 52:3195–201
   PubMed Web of Science ®Google Scholar
• Vyas S, Kannan M, Jain S, et al. (2004). Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37–49
   PubMed Web of Science ®Google Scholar
• Xie Y, Aillon KL, Cai S, et al. (2010). Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm 392:156--63
   PubMed Web of Science ®Google Scholar
• Young DB. (2001). Stimulate the phagocytes. Tuberculosis (Edinb) 81:257–8
   PubMed Web of Science ®Google Scholar
• Zhang S, Kawakami K. (2010). One-step preparation of chitosan solid nanoparticles by electrospray deposition. Int J Pharm 397:211–17
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li A, Wang Z, et al. (2008). Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. J Drug Target 16:679–87
   PubMed Web of Science ®Google Scholar